Paroxetine

Paroxetine has been studied in 18 papers since 2016: 1 trial and 4 observational studies in people, 3 in animals, 10 reviews; 9 in the past year. It is an approved medicine. The newest paper, Oct 27, 2026: “Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising”.

InterventionApproved 1992

18 papers study it7 more mention it16 findingsUpdated

PubChemChEBIMeSH

2 new papers in 30 daysSee all 25 papers on paroxetine

At a glance

The findings reach people, from one lab or study; independent labs found the same change in worms or flies. 6 independent labs in 5 countries; 95 trials, 3 about aging, 60 with no results posted.

“At 12 weeks, the paroxetine group showed greater reduction in total MRS score compared with placebo (mean 16.9 ± 7.7 vs. 22.6 ± 6.1; mean difference -5.7, 95% CI -8.6 to -2.8; P < 0.001).”
Paroxetine versus placebo for the management of vasomotor symptoms in surgical menopause: A pilot double-blind randomized clinical trialInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026doi:10.1002/ijgo.71093

1 of its findings points the other way.

Worms or flies: replicated by independent labs. Mice and humans: a single group. Cells: nothing yet.
  • 6 independent labs in 5 countries
  • 1 finding against
  • 95 trials, 3 about aging, 60 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 1 of 14 findings with company ties
  • Human trial1
  • Humans4
  • Animals1
  • Model organisms2

Studies in people

1 study gave paroxetine to people and measured what changed.

What changedDesignPeopleSource

down: Decreases menopause Rating Scale scoremean difference -5.7, 95% CI -8.6 to -2.8, P < 0.001

up: Improves quality of lifemean difference 4.1, 95% CI 1.7 to 6.5, P = 0.001

Randomized trial12 weeks90 peopleWomen<48 yearsMidlife adults; Patient cohortsInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, May 22, 2026

What did studies of paroxetine find?

13

Studies of paroxetine measured 13 outcomes, among them lifespan, menopausal vasomotor symptoms and quality of life.

Lifespan

upin worms2downin worms1

2 studies
  1. Paroxetine shortens lifespan in worms.

    “high doses consistently reduced lifespan”

    Model organismshigh doses

    The effects of paroxetine on lifespan, feeding behavior, and other physiological parameters in the nematode C. elegans under a modified bacterial diet

    Experimental gerontology

  2. Paroxetine extends lifespan in worms (when exposure began early).

    “low-dose paroxetine extended lifespan when exposure began early”

    Model organismswhen exposure began earlylow-dose

    The effects of paroxetine on lifespan, feeding behavior, and other physiological parameters in the nematode C. elegans under a modified bacterial diet

    Experimental gerontology

  3. Paroxetine extends lifespan in worms.

    “The results showed that paroxetine can prolong lifespan”

    Model organisms

    Paroxetine promotes longevity via ser-7-dop-4-IIS axis in Caenorhabditis elegans

    GeroScience

Menopausal vasomotor symptoms

downin humans1

1 study
  1. Paroxetine decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).

    “non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”

    ReviewMHT contraindicated or not preferred

    Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising

    Drugs & Therapy Perspectives

More on Menopausal vasomotor symptoms

Quality of life

upin humans1

1 study
  1. Paroxetine improves quality of life in humans (mean difference 4.1, 95% CI 1.7 to 6.5, P = 0.001).

    “SF-36 scores also improved more with paroxetine (91.0 ± 6.4 vs. 86.9 ± 4.8; mean difference 4.1, 95% CI 1.7 to 6.5; P = 0.001).”

    Human trial20 mg/day12 weeksfemalesn = 90

    Paroxetine versus placebo for the management of vasomotor symptoms in surgical menopause: A pilot double-blind randomized clinical trial

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Menopause Rating Scale score

downin humans1

1 study
  1. Paroxetine decreases menopause Rating Scale score in humans (mean difference -5.7, 95% CI -8.6 to -2.8, P < 0.001).

    “At 12 weeks, the paroxetine group showed greater reduction in total MRS score compared with placebo (mean 16.9 ± 7.7 vs. 22.6 ± 6.1; mean difference -5.7, 95% CI -8.6 to -2.8; P < 0.001).”

    Human trial20 mg/day12 weeksfemalesn = 90

    Paroxetine versus placebo for the management of vasomotor symptoms in surgical menopause: A pilot double-blind randomized clinical trial

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Fat accumulation

no changein worms1

1 study
  1. Paroxetine showed no clear effect on fat accumulation in worms.

    “without causing fat accumulation”

    Model organisms

    The effects of paroxetine on lifespan, feeding behavior, and other physiological parameters in the nematode C. elegans under a modified bacterial diet

    Experimental gerontology

Food intake

upin worms1

1 study
  1. Paroxetine increases food intake in worms.

    “Paroxetine also increased food intake without causing fat accumulation”

    Model organisms

    The effects of paroxetine on lifespan, feeding behavior, and other physiological parameters in the nematode C. elegans under a modified bacterial diet

    Experimental gerontology

Lipofuscin accumulation

downin worms1

1 study
  1. Paroxetine decreases lipofuscin accumulation in worms.

    “paroxetine can prolong lifespan concomitant extension of healthspan as indicated by increasing mobility and reducing lipofuscin accumulation”

    Model organisms

    Paroxetine promotes longevity via ser-7-dop-4-IIS axis in Caenorhabditis elegans

    GeroScience

More on Lipofuscin accumulation

Mobility

upin worms1

1 study
  1. Paroxetine improves mobility in worms.

    “paroxetine can prolong lifespan concomitant extension of healthspan as indicated by increasing mobility and reducing lipofuscin accumulation”

    Model organisms

    Paroxetine promotes longevity via ser-7-dop-4-IIS axis in Caenorhabditis elegans

    GeroScience

Spatial working memory

no changein mice1

1 study
  1. Paroxetine showed no clear effect on spatial working memory in mice (APPswe/PS1dE9 transgenic mice).

    “it appears to have no effect on total number of granular neurons or spatial working memory.”

    AnimalsAPPswe/PS1dE9 transgenic mice9 months

    Neuron and neuroblast numbers and cytogenesis in the dentate gyrus of aged APPswe/PS1dE9 transgenic mice: Effect of long-term treatment with paroxetine

    Neurobiology of disease

Amyloid plaque load

downin mice1

1 study
  1. Paroxetine decreases amyloid plaque load in mice (APPswe/PS1dE9 transgenic mice).

    “Paroxetine treatment from 9 to 18months of age reduced hippocampal amyloidosis without affecting the number of neuroblasts or granular neurons.”

    AnimalsAPPswe/PS1dE9 transgenic micehippocampus9 months

    Neuron and neuroblast numbers and cytogenesis in the dentate gyrus of aged APPswe/PS1dE9 transgenic mice: Effect of long-term treatment with paroxetine

    Neurobiology of disease

More on Amyloid plaque load

All 13

What is paroxetine linked with?

1

Studies link paroxetine with breast cancer.

Breast cancer

downin humans1OR 0.62

1 study
  1. Paroxetine lowers the risk of breast cancer in humans (current users) (OR 0.62, 95% CI 0.43-0.88).

    “Paroxetine appeared protective, with a lower risk among current users (OR = 0.62; 95% CI: 0.43-0.88)”

    Reviewcurrent usersfemales

    The Binomy Antidepressants and ROS with Breast Cancer: Reanalysis of Evidence from Over Two Million Women with a Randomised Meta-analytic Approach

    Research SquarePreprint

More on Breast cancer

Has paroxetine been tested in people?

3 of 95 about aging

Yes: 1 trial and 4 observational studies in people have been published, and 95 trials are registered.

Approved

  • FDA Paxil

    Dec 29, 1992Depressive Disorder, Major, Generalized Anxiety Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Social Anxiety Disorder

  • FDA Paxil

    Jun 25, 1997Discontinued

  • FDA Paxil

    Oct 9, 1998Discontinued

  • FDA Paxil CR

    Feb 16, 1999Depressive Disorder, Major, Panic Disorder, Premenstrual Dysphoric Disorder, Social Anxiety Disorder

  • FDA Pexeva

    Jul 3, 2003Discontinued

  • FDA Brisdelle

    Jun 28, 2013menopause, vasomotor symptoms, moderate to severe vasomotor symptoms associated with menopause

Repurposing

All 40

Stopped

  • NCT00926835TerminatedMajor depressive disorder

    due to patient recruitment difficulties

Who is developing paroxetine?

3 companies: GlaxoSmithKline, Asceneuron and Teva Pharmaceuticals USA.

Companies

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 3Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 4Nov 2026: 09 papers in 12 months

See all 25 papers on paroxetine